Royalty Pharma (RPRX) Price Target: AI vs Analyst Consensus
Our AI model gives Royalty Pharma (RPRX) a 6-month price target of $60.12, representing 2.6% potential upside from the current price of $58.61. The forecast combines financial fundamentals, technical analysis, and 25+ alternative data signals, including hiring trends, web traffic, employee sentiment, and social media activity. Royalty Pharma’s current AI Score is 54/100 (Neutral).
What’s Driving the RPRX Price Target
These are the signals feeding Royalty Pharma’s AI price target — spanning financial fundamentals, technical analysis, and alternative data — grouped by their recent direction. Improving signals tend to support a higher target; declining signals weigh on it.
RPRX Stock Forecast for 2026
Our AI model gives Royalty Pharma (RPRX) a 6-month price target of $60.12 — 2.6% upside from the current price of $58.61 — implying a climb toward that level through the rest of 2026. The target updates daily as new RPRX financial, technical, and alternative-data signals come in.
RPRX Price Prediction for 2027–2030
AltIndex does not publish a multi-year model — alternative data is most predictive over the next 6–12 months. Extending the current trajectory as a simple linear extrapolation projects RPRX toward $68.68 by 2030, but long-range estimates carry far more uncertainty and should be treated as directional only. The more reliable signal is whether Royalty Pharma’s AI Score and the drivers above keep improving over time.
Royalty Pharma (RPRX) Monthly Price Forecast
| Month | Forecast | vs Current |
|---|---|---|
| Oct 2026 | $58.86 | +0.4% |
| Nov 2026 | $59.11 | +0.9% |
| Dec 2026 | $59.37 | +1.3% |
| Jan 2027 | $59.62 | +1.7% |
| Feb 2027 | $59.87 | +2.1% |
| Mar 2027 | $60.12 | +2.6% |
Straight-line projection from the latest price ($58.61) toward our 6-month AI target of $60.12. An estimate, not a month-by-month model.
See how AltIndex’s AI Score picks have performed →Similar companies
View All →
Frequently Asked Questions: Royalty Pharma Price Prediction
On September 11, Royalty Pharma (RPRX) was assigned a Hold with a target price of $60.12. This signal was predicated on several factors, including several proprietary signals.
The conviction in the pick is low due to the limited amount of alternative data available.
Based on Alternative Data, Royalty Pharma is a hold.
Alternative data suggests that it's recommended to approach Royalty Pharma (RPRX) with caution. While there are positive indicators, the overall assessment suggests a hold based on Alternative Data analysis. However, this information should not be considered financial advice.
With an AI score of 54, the RPRX stock forecast suggests stability.
To predict the price for RPRX in 2027, we can extrapolate the AI price target. This approach projects RPRX's price to reach $59.62.
To predict the price for RPRX in 2030, we can again extrapolate the AI price target. This approach projects RPRX's price to reach $68.68.
When predicting the price for RPRX, our approach incorporates multiple scores assessing different aspects of the company. The Brand score measures growth and engagement across social media channels, indicating audience reach. The Employee score evaluates workforce health, considering job postings, business outlook, and employee ratings. The Customer score examines engagement on websites, app downloads, and sentiment in stock forums. Lastly, the Fundamental score analyzes financial statements and analyst ratings. By evaluating this data, we gain a holistic view of the company's performance, enabling more informed price predictions.
Based on technical analysis of how the price has moved over the last 6 months, the likelihood of the price going up tomorrow is 41%. Note that this is a simplistic analysis and should be used with caution, as prices are influenced by a myriad of factors.
Know the moment Royalty Pharma’s price target changes
Get RPRX alerts
